BACKGROUND: In Africa, success of antiretroviral treatment (ART) seems to lag behind in children compared with adults, and high therapeutic failure rates have been reported. We aimed to identify prevalence and determinants of virological failure in HIV-infected children treated under programmatic conditions. METHODS: All patients <18 years on ART presenting to the HIV clinic at the Bamenda Regional Hospital, a secondary referral hospital in rural Cameroon, from September 2010 to August 2011, were enrolled in this cross-sectional study. Clinical data, self-reported adherence, CD4(+) T-cell counts and viral load were recorded. Therapeutic drug monitoring was performed on stored plasma samples. Determinants of virological failure were identified using descriptive statistics and logistic regression. RESULTS: A total of 230 children with a mean age of 8.9 years (sd 3.7) were included. At the time of analysis, the mean duration of HAART was 3.5 years (sd 1.7) and 12% had a CD4(+) T-cell count <200 cells/µl. In total, 53% of children experienced virological failure (>200 copies/ml). Among children on nevirapine (NVP), plasma levels were subtherapeutic in 14.2% and supratherapeutic in 42.2%. Determinants of virological failure included male sex, lower CD4(+) T-cell counts, subtherapeutic drug levels, longer time on ART and a deceased mother. Poor adherence was associated with subtherapeutic NVP plasma levels and advanced disease stages (WHO stage 3/4). CONCLUSIONS: This study demonstrates high virological failure rates and a high variability of NVP plasma levels among HIV-infected children in a routine ART programme in rural Cameroon. Strategies to improve adherence to ART in HIV-infected children are urgently needed.
BACKGROUND: In Africa, success of antiretroviral treatment (ART) seems to lag behind in children compared with adults, and high therapeutic failure rates have been reported. We aimed to identify prevalence and determinants of virological failure in HIV-infectedchildren treated under programmatic conditions. METHODS: All patients <18 years on ART presenting to the HIV clinic at the Bamenda Regional Hospital, a secondary referral hospital in rural Cameroon, from September 2010 to August 2011, were enrolled in this cross-sectional study. Clinical data, self-reported adherence, CD4(+) T-cell counts and viral load were recorded. Therapeutic drug monitoring was performed on stored plasma samples. Determinants of virological failure were identified using descriptive statistics and logistic regression. RESULTS: A total of 230 children with a mean age of 8.9 years (sd 3.7) were included. At the time of analysis, the mean duration of HAART was 3.5 years (sd 1.7) and 12% had a CD4(+) T-cell count <200 cells/µl. In total, 53% of children experienced virological failure (>200 copies/ml). Among children on nevirapine (NVP), plasma levels were subtherapeutic in 14.2% and supratherapeutic in 42.2%. Determinants of virological failure included male sex, lower CD4(+) T-cell counts, subtherapeutic drug levels, longer time on ART and a deceased mother. Poor adherence was associated with subtherapeutic NVP plasma levels and advanced disease stages (WHO stage 3/4). CONCLUSIONS: This study demonstrates high virological failure rates and a high variability of NVP plasma levels among HIV-infectedchildren in a routine ART programme in rural Cameroon. Strategies to improve adherence to ART in HIV-infectedchildren are urgently needed.
Authors: M H W Huibers; P Moons; M Cornelissen; F Zorgdrager; N Maseko; M B Gushu; O H Iwajomo; M Boele van Hensbroek; J C J Calis Journal: J Antimicrob Chemother Date: 2018-12-01 Impact factor: 5.790
Authors: Elizabeth D Lowenthal; Tafireyi Marukutira; Ontibile Tshume; Jennifer Chapman; Gabriel M Anabwani; Robert Gross Journal: AIDS Behav Date: 2015-11
Authors: Calixte Ida Penda; Francine Same Bebey; Danielle Kedy Mangamba; Else Carole Eboumbou Moukoko; Victoria Ngwa; Nicaise Makouet; Anne-Cécile Bissek; Blaise Dupont Minkemdefo; Ekoe Tetanye; Paul Koki Ndombo Journal: Pan Afr Med J Date: 2013-06-30
Authors: Jean Joel Bigna; Marie A Amougou; Serra Lem Asangbeh; Angeladine Malaha Kenne; Steve Raoul N Noumegni; Elodie T Ngo-Malabo; Jean Jacques Noubiap Journal: BMJ Open Date: 2017-06-30 Impact factor: 2.692
Authors: Anna Gamell; Lukas Muri; Alex Ntamatungiro; Daniel Nyogea; Lameck B Luwanda; Christoph Hatz; Manuel Battegay; Ingrid Felger; Marcel Tanner; Thomas Klimkait; Emilio Letang Journal: Open Forum Infect Dis Date: 2015-12-17 Impact factor: 3.835
Authors: Cissy Kityo; Ragna S Boerma; Kim C E Sigaloff; Elizabeth Kaudha; Job C J Calis; Victor Musiime; Sheila Balinda; Rita Nakanjako; T Sonia Boender; Peter N Mugyenyi; Tobias F Rinke de Wit Journal: J Antimicrob Chemother Date: 2017-09-01 Impact factor: 5.790